DGAP-Adhoc: Biotest AG: Biotest marked increase in sales and earnings recorded in 2007


Biotest AG / Final Results

22.02.2008 

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Biotest marked increase in sales and earnings recorded in 2007

Dreieich, 22 February 2008. The Biotest Group recorded sales totalling EUR
326.4 million in financial year 2007, according to preliminary figures,
which is 15.8% up on the figure for the previous year
(EUR 281.9 million). Earnings before interest and tax (EBIT) rose by 22.6%
to EUR 38.5 million (2006: EUR 31.4 million).

The EBIT reflects charges amounting to EUR 1.5 million resulting from the
acquisition of Nabi Biopharmaceuticals Inc. plasma proteins business which
was completed in December 2007. The charges relate to the higher
write-downs associated with the purchase price allocation. The sales
recorded by the plasma proteins business in the US since the acquisition
have not been posted in the accounts.

In the Pharmaceutical segment, Biotest sales totalled EUR 247.0 million,
representing a 20.5% increase on 2006, while in the Diagnostic segment,
Biotest was able to increase its sales by 3.3% to EUR 79.4 million, growth
attributable to the sustained success of the microbiology business.

Biotest will be announcing the final figures for financial year 2007 on 20
March 2008. For the year ahead, Biotest is forecasting sales of an order of
magnitude totalling EUR 400 million, with a 10% increase in EBIT compared
to the previous year.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and immunological diagnostics which are used, for
example, in blood transfusions and transplants. Biotest has around 1,800
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.

Biotest AG: 
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth
Tel: +49 (0)6103 801-338
Fax: +49 (0)6103 801-347
e-mail: michael_ramroth@biotest.de

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 
DGAP 22.02.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       Biotest AG
              Landsteinerstr. 5
              63303 Dreieich
              Deutschland
Phone:        +49 - 6103 / 801 - 0
Fax:          +49 - 6103 / 801 - 150
E-mail:       mail@biotest.de
Internet:     www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------